Description

Cerebrolysin

Neuropeptide Preparation | Prescription Pharmaceutical | Neurological Research Compound

Cerebrolysin® is a pharmaceutical preparation containing a standardized mixture of low-molecular-weight peptides and amino acids derived from porcine brain tissue. It is developed for neurological and neurovascular applications and is supplied as a solution for injection. The manufacturer, EVER Pharma, lists a strength of 215.2 mg/mL and describes indications including cerebrovascular disorders, stroke, craniocerebral trauma, and certain dementia-related conditions in markets where the product is approved.

Cerebrolysin has been investigated for its effects on neuronal signaling, neurotrophic mechanisms, neuroplasticity, and cellular responses associated with neurological injury and degeneration.

Key Characteristics

  • Product Name: Cerebrolysin®
  • Dosage Form: Injectable solution
  • Strength: 215.2 mg/mL
  • Composition: Standardized low-molecular-weight peptides and amino acids derived from porcine brain tissue
  • Category: Prescription neuropeptide preparation
  • Research Areas: Neurobiology, neuroprotection, neuroplasticity, stroke research, and neurological pharmacology
  • Administration: Medical supervision required

Research & Pharmacological Profile

Cerebrolysin has been studied for its potential influence on multiple neurological processes rather than acting through a single receptor target. Research has examined pathways associated with neurotrophic signaling, neuronal survival, neuroplasticity, synaptic function, and recovery following neurological injury.

Its multi-component peptide composition distinguishes Cerebrolysin from single-sequence synthetic peptides. Research therefore commonly focuses on the overall biological activity of the standardized preparation.

Research Applications

Cerebrolysin may be investigated in controlled clinical, pharmacological, or laboratory research involving:

  • Neuroprotection research
  • Neuroplasticity studies
  • Stroke and cerebrovascular research
  • Traumatic brain injury research
  • Neurodegeneration research
  • Neuronal survival and signaling
  • Synaptic-function studies
  • Cognitive and neurological research
  • Pharmacokinetic and pharmacodynamic investigations
  • Analytical characterization of peptide preparations

Research Advantages

Multi-Peptide Neurobiological Preparation

Provides a standardized peptide preparation containing multiple low-molecular-weight components rather than a single synthetic peptide.

Neurological Research Utility

Has an established research history in areas involving stroke, brain injury, neurodegeneration, and neuronal function.

Neuroplasticity Research

Provides a model for investigating biological mechanisms associated with neuronal adaptation and repair.

Established Pharmaceutical Preparation

Unlike many experimental peptides, Cerebrolysin is marketed as a prescription medicine in certain countries, with manufacturer-specific pharmaceutical documentation.

Product Specifications

Specification Details
Product Name Cerebrolysin®
Form Injectable solution
Strength 215.2 mg/mL
Composition Low-molecular-weight peptides and amino acids
Source Porcine brain-derived
Category Prescription neuropeptide preparation
Research Areas Neurology & neurovascular research
Documentation Manufacturer documentation / COA

Quality & Documentation

For pharmaceutical or legitimate research applications, product documentation may include:

  • Product identity
  • Peptide/protein composition specifications
  • Concentration
  • Batch or lot number
  • Sterility information
  • Stability information
  • Certificate of Analysis or batch-release documentation
  • Manufacturer’s prescribing and technical information

Because Cerebrolysin is a complex biological preparation rather than a single defined peptide sequence, manufacturer-specific documentation is particularly important when characterizing the material.

Pharmaceutical Status

Cerebrolysin is a prescription medication in countries where it is registered. EVER Pharma states that it is not registered or approved for sale in the United States by the FDA. Regulatory status and approved indications therefore vary by country.

Important Safety & Regulatory Disclaimer

Cerebrolysin is a pharmacologically active prescription medicine, not a dietary supplement or general-purpose research chemical. It should be used only within the regulatory and medical framework applicable to the specific country and product.

This description is provided for scientific, product-identification, pharmaceutical, and legitimate research purposes. It does not provide dosing or injection instructions and does not recommend self-administration or non-prescribed use.